Viatris Analyst Price Targets

Wall Street analyst price targets and consensus rating for Viatris (VTRS).

Price Target Range — 11 Quarters

Analyst Consensus — 11 Analysts

7Buy

3Hold

1Sell

Consensus RatingBuy# Analysts11Avg. Consensus PT$17Upside to Avg. PT-4.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 5, 2026	UBS	Ashwani Verma	PT Raise	Buy	$23→$26
Sep 23, 2026	Oppenheimer	Les Sulewski	Initiate	Outperform	$25
Sep 16, 2026	Piper Sandler	David Amsellem	PT Raise	Neutral	$12→$13
Sep 9, 2026	Leerink Partners	Daniel Clark	Initiate	Outperform	$20
Sep 8, 2026	Argus Research	Jasper Hellweg	PT Raise	Buy	$15→$20
May 19, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$17→$22
May 8, 2026	JP Morgan	Chris Schott	PT Raise	Neutral	$17→$18
May 8, 2026	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$18→$20
Mar 24, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$15→$17
Jan 28, 2026	Piper Sandler	David Amsellem	PT Raise	Neutral	$9→$12
Jan 16, 2026	Argus Research	—	Upgrade	Hold→Buy	$15
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Overweight	$15
Oct 15, 2025	Truist Securities	Srikripa Devarakonda	Initiate	Buy	$15
Jun 6, 2025	Goldman Sachs	Matt Dellatorre	Initiate	Neutral	$10
Mar 7, 2025	Jefferies	Glen Santangelo	PT Cut	Buy	$15→$13
Mar 5, 2025	Piper Sandler	David Amsellem	PT Cut	Neutral	$14→$10
Feb 28, 2025	Barclays	Balaji Prasad	PT Cut	Underweight	$12→$9
Feb 28, 2025	B of A Securities	Jason Gerberry	PT Cut	Underperform	$11→$10
Dec 6, 2024	Piper Sandler	David Amsellem	PT Raise	Neutral	$13→$14
Nov 8, 2024	Barclays	Balaji Prasad	PT Raise	Underweight	$11→$12

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Maintains Buy on Viatris, Raises Price Target to $26

UBS analyst Ashwani Verma maintains Viatris (NASDAQ:VTRS) with a Buy and raises the price target from $23 to $26.

Benzinga Newsdesk

PRO
Oppenheimer Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $25

Oppenheimer analyst Les Sulewski initiates coverage on Viatris (NASDAQ:VTRS) with a Outperform rating and announces Price Target of $25.

Benzinga Newsdesk

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields

Analysts review high-yield healthcare stocks CVS, Viatris and Medtronic, citing ratings, price targets, dividend yields and recent company news.

Avi Kapoor

PRO
Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $13

Piper Sandler analyst David Amsellem maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $12 to $13.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $20

Leerink Partners analyst Daniel Clark initiates coverage on Viatris (NASDAQ:VTRS) with a Outperform rating and announces Price Target of $20.

Benzinga Newsdesk

PRO
Argus Research Maintains Buy on Viatris, Raises Price Target to $20

Argus Research analyst Jasper Hellweg maintains Viatris (NASDAQ:VTRS) with a Buy and raises the price target from $15 to $20.

Benzinga Newsdesk

Viatris Inc

Viatris Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Maintains Buy on Viatris, Raises Price Target to $26

PRO
Oppenheimer Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $25

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields

PRO
Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $13

PRO
Leerink Partners Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $20

PRO
Argus Research Maintains Buy on Viatris, Raises Price Target to $20

People Also Watch

People Also Watch

Viatris Inc

Viatris Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Maintains Buy on Viatris, Raises Price Target to $26

PROOppenheimer Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $25

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields

PROPiper Sandler Maintains Neutral on Viatris, Raises Price Target to $13

PROLeerink Partners Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $20

PROArgus Research Maintains Buy on Viatris, Raises Price Target to $20

People Also Watch

People Also Watch

PRO
UBS Maintains Buy on Viatris, Raises Price Target to $26

PRO
Oppenheimer Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $25

PRO
Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $13

PRO
Leerink Partners Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $20

PRO
Argus Research Maintains Buy on Viatris, Raises Price Target to $20